Axogen (AXGN) Return on Capital Employed (2011 - 2026)
Axogen's (AXGN) quarterly Return on Capital Employed came in at 3.93% in Q1 2026, down 371.0% year-on-year from 1.45% in Q1 2025, and up 2.14% quarter-over-quarter from 4.02% in Q4 2025.
Axogen (AXGN) Return on Capital Employed (2011 - 2026) Analysis & Trends
Axogen's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 3.93% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 371.0% year-over-year to 3.93% in Q1 2026; TTM through Mar 2026 was 3.93%, a 371.0% decrease from a year earlier, with the FY2025 full-year figure at 4.15%, down 221.0% from the prior year.
- Return on Capital Employed climbed to 3.93% in Q1 2026 per AXGN's latest filing, from 4.02% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 2.15% in Q3 2025 and bottomed at 18.04% in Q2 2022.
- The 5-year median for Return on Capital Employed is 11.07% (2024), against an average of 9.24%.
- Across the five-year window, Return on Capital Employed plunged 718 bps in 2022 and jumped 1102 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 17.3% in 2022, then rose by 25 bps to 12.98% in 2023, then soared by 85 bps to 1.97% in 2024, then sank by 104 bps to 4.02% in 2025, then rose by 2 bps to 3.93% in 2026.
- Per Business Quant, the three latest AXGN Return on Capital Employed figures stand at 3.93% (Q1 2026), 4.02% (Q4 2025), and 2.15% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 24.24% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 9.30% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 8.38% |
| 10 | Axogen | 2.12 Bn | 2.02 Bn | 46.19 Mn | -3.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.93% |
| Dec 31, 2025 | -4.02% |
| Sep 30, 2025 | 2.15% |
| Jun 30, 2025 | 0.97% |
| Mar 31, 2025 | -0.22% |
| Dec 31, 2024 | -1.97% |
| Sep 30, 2024 | -5.08% |
| Jun 30, 2024 | -7.43% |
| Mar 31, 2024 | -11.07% |
| Dec 31, 2023 | -12.98% |
| Sep 30, 2023 | -14.34% |
| Jun 30, 2023 | -14.83% |
| Mar 31, 2023 | -15.03% |
| Dec 31, 2022 | -17.30% |
| Sep 30, 2022 | -17.10% |
| Jun 30, 2022 | -18.04% |
| Mar 31, 2022 | -16.95% |
| Dec 31, 2021 | -13.76% |
| Sep 30, 2021 | -13.61% |
| Jun 30, 2021 | -10.86% |